SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (14644)9/16/2000 8:56:01 PM
From: Cacaito  Respond to of 17367
 
Blue, I am proud of you. 70% reduction is not proven, it was observed in an underpowered study, it is not proven, ask your Giroir, ask your prperson, xoma, fda.



To: Bluegreen who wrote (14644)9/16/2000 8:57:25 PM
From: Cacaito  Read Replies (1) | Respond to of 17367
 
I am saying:neuprex does not qualify for subpart E approval,
ASK xoma that tried hard and could not get it, What do you xoma was trying to do, coffe talk at the Maryland CAFE.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News